Strong Balance Sheet And Reduced LeverageSupriya's equity ratio nearly doubled to 89.6% by 2025 and debt-to-equity markedly declined, indicating materially lower financial risk and greater capacity to fund growth internally. This durable improvement strengthens solvency, lowers refinancing risk, and supports strategic investments over the next several quarters.

Improving Cash Generation; FCF Turned PositiveFree cash flow turning positive in 2025 signals the business is converting profits into distributable cash, improving funding for capex, working capital and deleveraging. Strong operating cash versus net income suggests quality earnings and greater resilience to cyclical pressure in API demand over 2–6 months.

Sustained Revenue Growth And Improving MarginsConsistent top-line expansion alongside rising net profit margin demonstrates scalable operations and improving cost efficiency. Doubling revenue over five years with higher margins supports durable earnings power, stronger internal funding and competitive positioning in API supply across domestic and export customers.

Bears Say

Free Cash Flow VolatilityAlthough FCF is positive in 2025, historical swings in free cash flow indicate timing variability in capex and working capital needs. This can constrain consistent capital returns or disciplined investment pacing and raises execution risk for multi-quarter projects or margin-stabilizing investments.

Moderate EPS GrowthEarnings-per-share growth near 6.2% is modest given the company's margin expansion and revenue gains. Slower EPS compounding can limit investor returns over time and suggests either share count dynamics, one-off items, or that net income growth may not yet translate proportionally to per-share gains.

Limited Disclosure On Customer/geography ConcentrationLack of disclosed customer and geographic revenue breakdown obscures concentration risk and visibility into export exposure. For an API supplier, customer concentration or reliance on a few markets can materially affect demand stability and negotiating leverage, elevating structural revenue risk.

Supriya Lifescience Limited News

Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results

An announcement from Supriya Lifescience Limited ( ($IN:SUPRIYA) ) is now available. Supriya Lifescience Limited has announced the...

2M ago

Supriya Lifescience Schedules Earnings Call to Discuss Financial Performance

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has issued an announcement. Supriya Lifescience Limited has announced an upcoming earnings...

3M ago

SUPRIYA FAQ

What was Supriya Lifescience Limited’s price range in the past 12 months?

Supriya Lifescience Limited lowest stock price was ₹556.85 and its highest was ₹841.70 in the past 12 months.

What is Supriya Lifescience Limited’s market cap?

Supriya Lifescience Limited’s market cap is ₹55.56B.

When is Supriya Lifescience Limited’s upcoming earnings report date?

Supriya Lifescience Limited’s upcoming earnings report date is Jun 02, 2026 which is in 100 days.

How were Supriya Lifescience Limited’s earnings last quarter?

Supriya Lifescience Limited released its earnings results on Feb 09, 2026. The company reported ₹6.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.2.

Is Supriya Lifescience Limited overvalued?

According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Supriya Lifescience Limited pay dividends?

Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.13%. See more information on Supriya Lifescience Limited dividends here

What is Supriya Lifescience Limited’s EPS estimate?

Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Supriya Lifescience Limited have?

Supriya Lifescience Limited has 80,482,800 shares outstanding.

What happened to Supriya Lifescience Limited’s price movement after its last earnings report?

Supriya Lifescience Limited reported an EPS of ₹6.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.803%.

Which hedge fund is a major shareholder of Supriya Lifescience Limited?

Currently, no hedge funds are holding shares in IN:SUPRIYA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Supriya Lifescience Limited

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.